Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9319000 | Early Human Development | 2005 | 8 Pages |
Abstract
In vitro and in vivo results are consistent with the view that the nucleoside reverse transcriptase inhibitors cross the human placenta and produce significant pharmacological concentrations in the fetal circulation. Nevirapine, the only studied non-nucleoside reverse transcriptase inhibitor, reach the equilibrium between the fetal and maternal concentration, whereas the protease inhibitors have a poor transfer across the human placenta.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Gian Maria Pacifici,